Cargando…
Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have onl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598628/ https://www.ncbi.nlm.nih.gov/pubmed/36290499 http://dx.doi.org/10.3390/bioengineering9100531 |
_version_ | 1784816387229745152 |
---|---|
author | Qauli, Ali Ikhsanul Yoo, Yedam Marcellinus, Aroli Lim, Ki Moo |
author_facet | Qauli, Ali Ikhsanul Yoo, Yedam Marcellinus, Aroli Lim, Ki Moo |
author_sort | Qauli, Ali Ikhsanul |
collection | PubMed |
description | The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have only looked at the effects of mexiletine on action potential duration (APD) or QT interval reduction. We further investigated mexiletine’s effects on cardiac cells through simulations of single-cell (behavior of alternant occurrence) and 3D (with and without mexiletine). We discovered that mexiletine could shorten the cell’s APD and change the alternant’s occurrence to a shorter basic cycle length (BCL) between 350 and 420 ms. The alternant also appeared at a normal heart rate under the A1656D mutation. Furthermore, the 3D ventricle simulations revealed that mexiletine could reduce the likelihood of a greater spiral wave breakup in the A1656D mutant condition by minimizing the appearance of rotors. In conclusion, we found that mexiletine could provide extra safety features during therapy for LQT3 patients because it can change the alternant occurrence from a normal to a faster heart rate, and it reduces the chance of a spiral wave breakup. Therefore, these findings emphasize the promising efficacy of mexiletine in treating LQT3 patients under the A1656D mutation. |
format | Online Article Text |
id | pubmed-9598628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95986282022-10-27 Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model Qauli, Ali Ikhsanul Yoo, Yedam Marcellinus, Aroli Lim, Ki Moo Bioengineering (Basel) Brief Report The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have only looked at the effects of mexiletine on action potential duration (APD) or QT interval reduction. We further investigated mexiletine’s effects on cardiac cells through simulations of single-cell (behavior of alternant occurrence) and 3D (with and without mexiletine). We discovered that mexiletine could shorten the cell’s APD and change the alternant’s occurrence to a shorter basic cycle length (BCL) between 350 and 420 ms. The alternant also appeared at a normal heart rate under the A1656D mutation. Furthermore, the 3D ventricle simulations revealed that mexiletine could reduce the likelihood of a greater spiral wave breakup in the A1656D mutant condition by minimizing the appearance of rotors. In conclusion, we found that mexiletine could provide extra safety features during therapy for LQT3 patients because it can change the alternant occurrence from a normal to a faster heart rate, and it reduces the chance of a spiral wave breakup. Therefore, these findings emphasize the promising efficacy of mexiletine in treating LQT3 patients under the A1656D mutation. MDPI 2022-10-07 /pmc/articles/PMC9598628/ /pubmed/36290499 http://dx.doi.org/10.3390/bioengineering9100531 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Qauli, Ali Ikhsanul Yoo, Yedam Marcellinus, Aroli Lim, Ki Moo Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model |
title | Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model |
title_full | Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model |
title_fullStr | Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model |
title_full_unstemmed | Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model |
title_short | Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model |
title_sort | verification of the efficacy of mexiletine treatment for the a1656d mutation on downgrading reentrant tachycardia using a 3d cardiac electrophysiological model |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598628/ https://www.ncbi.nlm.nih.gov/pubmed/36290499 http://dx.doi.org/10.3390/bioengineering9100531 |
work_keys_str_mv | AT qaulialiikhsanul verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel AT yooyedam verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel AT marcellinusaroli verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel AT limkimoo verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel |